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ABSTRACT
The concept of intrinsic efficacy has been enshrined in phar-
macology for half of a century, yet recent data have revealed
that many ligands can differentially activate signaling pathways
mediated via a single G protein-coupled receptor in a manner
that challenges the traditional definition of intrinsic efficacy.
Some terms for this phenomenon include functional selectivity,
agonist-directed trafficking, and biased agonism. At the ex-
treme, functionally selective ligands may be both agonists and
antagonists at different functions mediated by the same recep-
tor. Data illustrating this phenomenon are presented from se-
rotonin, opioid, dopamine, vasopressin, and adrenergic recep-
tor systems. A variety of mechanisms may influence this
apparently ubiquitous phenomenon. It may be initiated by dif-
ferences in ligand-induced intermediate conformational states,
as shown for the 2-adrenergic receptor. Subsequent mecha-
nisms that may play a role include diversity of G proteins,
scaffolding and signaling partners, and receptor oligomers.
Clearly, expanded research is needed to elucidate the proximal
(e.g., how functionally selective ligands cause conformational
changes that initiate differential signaling), intermediate (mech-
anisms that translate conformation changes into differential
signaling), and distal mechanisms (differential effects on target
tissue or organism). Besides the heuristically interesting nature
of functional selectivity, there is a clear impact on drug discov-
ery, because this mechanism raises the possibility of selecting
or designing novel ligands that differentially activate only a
subset of functions of a single receptor, thereby optimizing
therapeutic action. It also may be timely to revise classic con-
cepts in quantitative pharmacology and relevant pharmacolog-
ical conventions to incorporate these new concepts.
Receptor Pharmacology for the New
Millennium
For the last half-century, pharmacological theory has pos-
ited that ligands could be characterized by the nature of the
functional effects elicited by their interaction with their tar-
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get receptor. These effects are governed by two important
properties: 1) affinity, the property of attraction between a
ligand and its receptor, and 2) efficacy, the property that
allows ligands, once bound, to produce a response (Kenakin,
1997). This concept has led to the classification of receptor
ligands as full agonists, partial agonists, neutral antagonists,
or inverse agonists. Perhaps the key idea that governs this
classification is the notion of “intrinsic efficacy”, originally
proposed by Furchgott (1966) as a measure of the stimulus
per receptor molecule produced by a ligand. According to this
notion, full agonists possess sufficiently high intrinsic effi-
cacy, such that they maximally stimulate all cellular re-
sponses linked to a given receptor. Partial agonists possess
lower degrees of intrinsic efficacy (leading to submaximal
responses), whereas inverse agonists reduce constitutive (li-
gand-independent, basal) receptor signaling. Neutral antag-
onists possess no intrinsic efficacy but occupy the receptor to
block the effects of full, partial, or inverse agonists. This idea
has also led to the assumption, dearly held in pharmacology,
that the ability of the ligand to impart (or reduce) stimulus
once that ligand is bound to the receptor is an inherent
property of the ligand-receptor complex. Intrinsic efficacy is
thus differentiated from the more operational term “intrinsic
activity” (Ariens, 1954) that simply refers to the maximal
effect (Emax) of a ligand relative to a reference agonist in a
given experimental system.
Therefore, in classical pharmacological terms, intrinsic ef-
ficacy has been viewed as a system-independent parameter
that is constant for each ligand at a given receptor, irrespec-
tive of where that receptor is expressed. Any differences in
the expression of agonism by a ligand between cell and tissue
types were assumed simply to reflect differences in receptor
density and/or the strength of stimulus-response coupling. In
other words, the classification of compounds on the basis of
intrinsic efficacy only allowed for variations in the quantity
of the stimulus that was imparted to the cell, but not the
quality. A full agonist would be expected to activate all of the
signaling pathways linked to a receptor to the same degree as
the endogenous ligand for that receptor. In contrast, a ligand
that antagonizes one signaling pathway via a specific recep-
tor should antagonize every pathway coupled to that receptor
to the same extent. One consequence of this theory was the
weight it added to Ehrlich’s idea of a therapeutic “magic
bullet”. It led to a focus on discovery of new receptor ligands
with high affinity and having specific functional characteris-
tics at a single target. Although modern drug discovery re-
cently has recognized that there is value in ligands that act
by simultaneously targeting multiple receptors (Roth et al.,
2004), there is still the widespread view that the character-
istics of ligands at target receptors can be described by their
“intrinsic efficacy”. In fact, the notion that intrinsic efficacy is
system-independent forms a major underlying premise in
drug discovery today—that the pharmacological characteris-
tics of a drug tested in an experimental model system can be
extrapolated to all systems. As discussed below, this premise
is frequently incorrect.
This change in perspective has been spurred by data
emerging within the past decade in which certain ligands
were shown to have quite diverse functional consequences
mediated via a single receptor. Because these data were
clearly not consistent with classical pharmacological con-
cepts, they were often dismissed as artifacts caused by dif-
ferences in “strength of signaling”, receptor reserve, undetec-
ted interactions with unknown receptors, effects of trace
contaminants or drug metabolites, and/or similar mecha-
nisms. Yet as more and more data have been amassed with a
variety of different receptors, it is becoming clear that the
classical concept of “intrinsic efficacy” as a system-indepen-
dent constant, although once having conceptual utility, is
probably not correct. Indeed, almost every researcher reach-
ing this conclusion felt it important enough to coin their own
descriptive terms that now include “functional selectivity”,
“agonist-directed trafficking of receptor stimulus”, “biased
agonism”, “protean agonism”, “differential engagement”, and
“stimulus trafficking” (to name just a few).
It was the concatenation of this research that led to two
symposia at the Experimental Biology 2005 meeting whose
essence is captured in this Perspective. We propose that
ligands induce unique, ligand-specific receptor conformations
that frequently can result in differential activation of signal
transduction pathways associated with that particular recep-
tor (Roth and Chuang, 1987; Kenakin, 1995; Mailman et al.,
1997, 1998; Clarke and Bond, 1998; Ghanouni et al., 2001;
Gonzalez-Maeso et al., 2003). This differential activation
may be expressed as differences in intrinsic activity and/or
potency at one signaling pathway versus another that are not
due to differences in affinity at the mediating receptor.
Throughout this article, this concept is termed “functional
selectivity”, yet it must be made clear that this is not a
IUPHAR-accepted convention. We chose it for the sympo-
sium titles, because it is a purely operational term that can
accommodate one or any combination of several involved
mechanisms (vide infra). Indeed, as is noted below, the par-
ticipants suggested that it may be timely to settle on conven-
tions that will help to focus the relevant literature in this
area. Although most of the research that was presented is
recent and uses a variety of modern techniques, we are aware
that ideas related to “functional mismatches” had been the-
orized earlier, sometimes going back decades (Portoghese,
1965; Jim et al., 1985; Roth and Chuang, 1987). We summa-
rize below some of the data from our laboratories that sup-
port this concept, but we recognize that others also have
made similar observations and come to similar conclusions.
Examples of Functional Selectivity
Atypical Agonists of 5-HT2 Serotonin Receptors
There have been a plethora of observations of functional
selectivity made by a number of groups investigating seroto-
nin receptor systems. The effector that has been best char-
acterized with respect to 5-HT2 signaling involves the Gq
stimulation of phospholipase C (PLC), leading to the forma-
tion of inositol phosphates (IP) and diacylglycerol, thereby
modulating intracellular calcium [Ca2]i (Hoyer et al., 1994).
This receptor family also has been shown to mediate the
release of arachidonic acid (AA), presumably through the
activation of phospholipase A2 (PLA2) (Felder et al., 1990), an
enzyme that acts on membrane phospholipids.
Berg et al. (1998b) reported the capability of certain sero-
tonergic ligands to differentially activate these signal trans-
duction pathways associated with the human serotonin
5-HT2A and 5-HT2C receptors. They observed that the rela-
tive efficacy of a series of ligands for each of the receptors
differed depending upon whether PLC-mediated accumula-
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tion of IP or PLA2-mediated release of AA was measured (Fig.
1). Important aspects of the experimental design were that
responses to the reference drug were obtained along with
each test ligand in every experiment, and both signal trans-
duction responses were measured simultaneously from the
same cells, thereby obviating methodological reasons for re-
sponse-dependent differences in relative agonist efficacy
(Berg et al., 1998a). The significance of these differences in
relative efficacy was further supported by the lack of differ-
ence in relative agonist efficacy between the PLC-IP response
and increases in [Ca2]i levels of which agonists would not be
expected to regulate differentially.
Further studies of the 5-HT2C receptor demonstrate that
the ability of agonists to activate receptor desensitization
mechanisms also seems to be ligand-dependent (Fig. 1).
Marked differences are observed in the relative efficacy of
agonists to rapidly desensitize the 5-HT2C-mediated PLC-IP
and PLA2-AA response pathways, but these efficacies of de-
sensitization did not correspond to the relative efficacies of
pathway activation (Stout et al., 2002). Examination of the
5-HT2C receptor molecular structure indicates that the sec-
ond intracellular loop plays a crucial role in transmitting
agonist-specific information to the PLC-IP and PLA2-AA sig-
nal response pathways. It was observed that, by changing
three amino acids within this region (positions 156, 158, and
160 from Ile-Asn-Ile to either Val-Ser-Val or Val-Glu-Val),
the capacity of 5-HT2C agonists to differentially signal
through these response pathways was compromised (Berg et
al., 2001). This example, a result of mRNA editing, highlights
the importance of how subtle changes in receptor structure
and its effect on conformation (Visiers et al., 2001) can ulti-
mately affect the cellular signaling responses.
The concept of functional selectivity also applies to com-
pounds that are classified as inverse agonists, some of which
may have different functional characteristics at other signal-
ing pathways mediated by the targeted receptor. An example
of this is SB 242084 (Cussac et al., 2002), a functionally
selective ligand that is a strong inverse agonist for 5-HT2C
receptor-mediated PLA2-AA release and Gi but an agonist
for PLC-IP (De Deurwaerdere et al., 2004). These observa-
tions further support the notion of ligand-induced differen-
tial signaling and highlight the importance of referencing
response and the conditions of that response when describing
the intrinsic activity of a ligand.
Other interesting data have arisen from studies that
looked specifically at hallucinogens and their differential sig-
naling through the 5-HT2A receptor. Although the PLC-IP
effector is an easy pathway to evaluate experimentally, there
had been no proof that the hallucinogenic effects of com-
pounds, such as LSD, rely on its activation. A recent report
(Rabin et al., 2002) emphasized that there is no correlation
between hallucinogenic activity and activation of the PLC
effector pathway. Kurrasch-Orbaugh et al. (2003b) compared
the effects of LSD and DOB (a hallucinogenic phenethyl-
amine derivative) on 5-HT2A receptor-mediated accumula-
tion of IP3 and found that both had significant potency for
this pathway (EC50  10 and 70 nM, respectively), yet LSD
demonstrated little intrinsic activity (22%) relative to that
(80%) of DOB.
The discrepancies between PLC activation and in vivo
pharmacology led to the investigation of other effector path-
ways associated with 5-HT2A receptor activation. As men-
tioned previously, 5-HT2A receptor stimulation also leads to
the release of AA. A series of 5-HT2A agonists was found to
have varying potencies and intrinsic activities for the accu-
mulation of IP3 or AA (Fig. 2), but it appeared that activation
of the latter pathway was more likely to be associated with
hallucinogenic effects than IP3 accumulation (Kurrasch-Or-
baugh et al., 2003a). Further investigation of hallucinogen-
mediated release of AA demonstrated that this functional
pathway is more complex than originally thought. In vitro,
after a 30-min agonist stimulation, it has been shown that
AA signaling probably involves Gi/o and G12/13, as well as
G, Rho, mitogen-activated protein kinase kinase 1/2, and
p38 MAPK (Kurrasch-Orbaugh et al., 2003a), indicating that
more than one signaling cascade is responsible for 5-HT2A
receptor-mediated AA release. More recent studies have
demonstrated that 5-HT2A receptor activation also leads to
the formation of the 2-arachidonylglycerol, an endocannabi-
noid whose formation is partially dependent on the PLC-
mediated accumulation of IP3 (Parrish and Nichols, 2006).
Therefore, it seems that activation of the 5-HT2A receptor
leads to the production of at least three distinct biochemical
signals (IP3/diacylglycerol, AA, and 2-arachidonylglycerol)
and that the relative activation of these pathways varies with
the ligand under investigation. Moreover, the “transcriptome
fingerprints” of various agonists activating only the 5-HT2A
receptors were shown to differ (Gonzalez-Maeso et al., 2003).
However, at present, there is no clear evidence to suggest
what structural characteristics of a ligand promote the acti-
vation of one effector over the others. The induction of unique
receptor conformations by each ligand would, in theory, pro-
mote distinct affinities and coupling efficiencies to the vari-
ous G proteins endogenously expressed in cell models and
also possibly to other proteins that interact with the recep-
tors in modulating signal transduction. Virtual docking of
enantiomeric phenethylamines into a homology model of the
5-HT2A receptor has been employed to investigate the possi-
bility that subtle structural differences among ligands might
be responsible for distinct receptor conformations and hence
Fig. 1. Functional selectivity at the 5-HT2C receptor. Bars represent the
ratio of the maximal effect of the test ligands to that of the reference
ligand, 5-HT. Note, for example, that bufotenin is a full agonist at AA
release and a partial agonist at IP accumulation, whereas m-trifluoro-
methylphenylpiperazine (TFMPP) is a full agonist at IP accumulation but
has only partial intrinsic activity at AA release. Other examples violating
the classically held tenet of intrinsic efficacy (i.e., response independence)
are also seen in the data from Stout et al. (2002).
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the unique pharmacologies associated with a number of the
5-HT2A ligands (Parrish et al., 2005). These studies indicate
that there is much more research to be done before the
molecular determinants of functional selectivity in any
GPCR paradigm are to be elucidated (Parrish et al., 2005).
5-HT2 Serotonin Receptor “Antagonists” and Collateral
Efficacy
Most of the examples of compounds that seem to activate
5-HT receptors differentially are ligands that were originally
thought to be typical agonists, yet there are examples in
which presumed antagonists actually demonstrate an ago-
nist-like activity. For example, chronic antagonist treatment
often leads to compensatory receptor up-regulation (Hess et
al., 1988) that may be one of the mechanisms involved in the
resultant “supersensitivity” of receptor signaling (Schulz et
al., 1979). In spite of this fact, it has long been known that
chronic antagonist administration leads to apparent receptor
down-regulation and desensitization of signaling with some
GPCRs (for recent reviews, see Kenakin, 2005; O’Connor and
Roth, 2005). This paradoxical regulation of GPCRs by antag-
onists was discovered and has been most convincingly dem-
onstrated for 5-HT2 family serotonin receptors.
Peroutka and Snyder (1980) were the first to demonstrate
that chronic treatment with 5-HT2A antagonists leads to
apparent 5-HT2A receptor down-regulation in vivo—a finding
that has now been replicated in over 100 published studies
(see Gray and Roth, 2001 for review), of which many have
shed additional light on this phenomenon. It has been dem-
onstrated that: 1) antagonists induce 5-HT2A receptor inter-
nalization and down-regulation in vitro when cloned recep-
tors are expressed in heterologous expression systems (Berry
et al., 1996; Newton and Elliott, 1997; Willins et al., 1999;
Bhatnagar et al., 2001); 2) antagonists induce 5-HT2A recep-
tor internalization in vivo in individual cortical neurons (Wil-
lins et al., 1999); 3) antagonist-induced desensitization re-
quires internalization (Hanley and Hensler, 2002); and 4)
antagonist-induced receptor down-regulation does not occur
due to changes in receptor synthesis (Roth and Ciaranello,
1991; Anji et al., 2000). Antagonist-induced internalization,
an example of “collateral efficacy” (Kenakin, 2005), also has
been demonstrated with cholecystokinin and other peptide
receptors (Roettger et al., 1997; Sneddon et al., 2003).
These observations suggest that the antagonist-induced
internalization of 5-HT2A and other GPCRs may have ther-
apeutic potential. For example, Elphick et al. (2004) recently
demonstrated that the JC Virus—the causative agent of pro-
gressive multifocal leukoencephalopathy—uses 5-HT2A re-
ceptors to infect cells and that some 5-HT2A antagonists
known to induce receptor internalization can block this viral
infection. Further study has shown that antagonists that
induce 5-HT2A receptor internalization in vitro (e.g., mirtaz-
epine) are able to block viral infection, whereas those that do
not (e.g., cyproheptadine) are less protective (W. Attwood,
personal communication) (O’Connor and Roth, 2005). There-
fore, it stands to reason that prophylactic treatment with
5-HT2A antagonists with collateral efficacy is likely to be
therapeutic, whereas treatment with antagonists that fail to
internalize the 5-HT2A receptor is not (O’Connor and Roth,
2005). Indeed, antagonists with the ability to induce 5-HT2A
receptor down-regulation might be therapeutically useful, for
example, for individuals at risk for progressive multifocal
leukoencephalopathy as a side effect of treatment with drugs
like natalizumab (Engelhardt and Briskin, 2005; Ransohoff,
2005; Van et al., 2005).
Functional Selectivity at -Opioid, 2-Adrenergic, and V2
Vasopressin Receptors
Serotonergic receptors are not the only family of receptors
with which the phenomenon of functional selectivity has
been observed. There is both pharmacological and biochem-
ical evidence for the agonist-selective regulation of -opioid
and 2-adrenergic receptor(s) (2AR). Some of these observa-
tions were made in studies designed to determine the ability
of ligands to produce an endocytic effect on the receptor
under investigation, thereby affecting receptor regulation.
Using epifluorescence microscopy of epitope-labeled -opioid
receptor, it was possible to visualize differences in -opioid
receptor agonist induction of receptor endocytosis in trans-
fected fibroblasts (Keith et al., 1996) and in neurons express-
ing endogenous receptors in vivo (Sternini et al., 1996; Keith
et al., 1998). Furthermore, by comparing the “endocytic effi-
cacies” of these compounds with their intrinsic activities for
other effectors coupled to -opioid receptor (e.g., adenylate
cyclase activity and GIRK channel regulation), they were
able to illustrate functional differences among agonists that
were not predicted by the two-state receptor model. For ex-
ample, the opioid peptide DAMGO induces significant recep-
Fig. 2. Functional selectivity at 5-HT2A receptors. The panel on the left illustrates relative potency of two agonist ligands in stimulating PLC,
measured by the accumulation of inositol phosphates in a stable rat 5-HT2A NIH-3T3 cell line. The EC50 values for DOB and (R)-2C-B-CB are 23 and
43 nM, respectively, only 2-fold different, with similar intrinsic activities. By contrast, the panel on the right shows the potency of the same two ligands
in stimulating AA release from these cells, EC50 values of 58 nM and 1.6 M, respectively, their potencies differing in this signaling pathway by nearly
30-fold. Although DOB is clearly not functionally selective, (R)-2C-B-CB, a structurally related ligand, is 36-fold selective in stimulating the PLC
signaling pathway over AA production.
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tor endocytosis similar to methadone, whereas morphine elic-
its a much more subtle endocytic response (Keith et al., 1996;
Whistler et al., 1999). However, morphine is able to activate
GIRK channels via -opioid receptors in transfected fibro-
blasts with an intrinsic activity similar to or greater than
that of methadone (Whistler et al., 1999), and similar effects
have been reported in situ (Alvarez et al., 2002). These data
suggest that an alternative receptor model is in order, one
that takes into consideration at least two different active
receptor conformations that can be specifically induced, or
selected for, by a particular ligand.
Such observations have prompted further studies designed
to elucidate the mechanism behind differential receptor en-
docytosis. Significant evidence had suggested that ligand-
specific differential receptor phosphorylation of the -opioid
receptor was a potential mechanism by which downstream
cellular effectors could distinguish the different functional
effects elicited by ligands (Yu et al., 1997; Whistler and von
Zastrow, 1998; Zhang et al., 1998; He et al., 2002). Moreover,
a similar observation had been made by Benovic et al. (1988)
in the 2AR system in vitro. A recent study has examined
whether the 2AR has a single or multiple agonist-induced
phosphorylated states in an intact cell. Trester-Zedlitz et al.
(2005) incorporated a protein analytical approach that took
advantage of recent improvements in mass spectrometry
methods (specifically, matrix-assisted laser desorption ion-
ization-time of flight) and protein enrichment procedures
(e.g., stable isotope labeling with amino acids in culture and
immobilized metal affinity chromatography) that allow for
the biochemical analysis or “read-out” of ligand-induced post-
translational modifications to 2AR isolated from a stable
human embryonic kidney cell line. These studies indicate
that there are not only multiple phosphorylation sites be-
tween the third intracellular loop and carboxyl-terminal cy-
toplasmic domain of the 2AR but that there seems to be an
agonist bias that determines the specific phosphorylation
state (Trester-Zedlitz et al., 2005). Although mapping the
specific amino acid residues that are phosphorylated in re-
sponse to a specific ligand is still a work in progress, the
general site locations are consistent with previous studies of
ligand-induced desensitization and GRK activity (Hausdorff
et al., 1991; Tran et al., 2004). These data lend support to the
hypothesis of differential regulation of receptor endocytosis
by distinct ligands via agonist-selective posttranslational
modifications, such as phosphorylation.
More pertinent to the clinic are some preliminary data that
suggest that there may be a genetic component to functional
selectivity as it relates to specific physiological syndromes. A
screening approach has identified C5a complement receptor
mutations that separate ligand dependence of endocytosis
from signaling (Baranski et al., 1999; Whistler et al., 2002). A
more recent study reached a similar conclusion for the V2
vasopressin receptor (V2R) and suggested that this distinc-
tion is the basis of a newly defined human genetic disease.
Several patients, presumptively diagnosed with the syn-
drome of inappropriate antidiuretic hormone secretion, were
shown to express one of two gain-of-function point mutations
of Arg137 (to Cys and Leu) of the V2R (Feldman et al., 2005).
Arg137 is located in the conserved “DR(Y/H)” motif of the
receptor, and the mutations were shown to cause constitutive
activation of receptor signaling, defining the “nephrogenic
syndrome of inappropriate antidiuresis” or NSIAD. This
study is particularly interesting because the alternate muta-
tion of precisely the same residue to His causes reduced
receptor signaling and the opposite disease state of nephro-
genic diabetes insipidus (Rosenthal et al., 1993). Interest-
ingly, the nephrogenic diabetes insipidus mutant V2R is
weakly activated by agonist ligands because it is bound to
arrestins and internalized in a constitutive (or ligand-inde-
pendent) manner (Barak et al., 2001). Conversely, the mu-
tant V2R producing NSIAD exhibits constitutive signaling,
yet its internalization and arrestin association are strongly
ligand-dependent (Vargas et al., submitted for publication).
This mutational “reversal” in ligand dependence for signal-
ing and internalization supports the hypothesis that there
may exist multiple ligand-induced conformations of the V2R,
differing in relative signaling and internalization activities,
and that these may underlie essentially opposite human
disease states.
Functional Selectivity at D2L and D1 Dopamine Receptors
Dopamine receptors represent another subset of GPCRs
that have been observed to differentially activate associated
signaling cascades in response to certain compounds. In fact,
much of the work on functional selectivity through dopamine
receptors was an unexpected result of efforts directed at the
rational discovery of novel D1 dopamine ligands (Charifson et
al., 1989; Mottola et al., 1996; Qandil et al., 2003). When
dihydrexidine (DHX), the first high-affinity full agonist for
the D1 dopamine receptor was characterized (Lovenberg et
al., 1989), it was found to have only a 10-fold selectivity for D1
versus D2 receptors (Brewster et al., 1990; Mottola et al.,
1992). DHX and its congener N-propylDHX were initially
characterized as full agonists at the D2 receptor, because
they were as efficacious as dopamine in inhibiting cAMP
synthesis and efflux in striatal slices, inhibiting prolactin
release in vivo, and stimulating GTPS binding in rat sub-
stantia nigral tissue (Mottola et al., 1992; Kilts et al., 2002).
However, further characterization of the functional profile of
these compounds demonstrated that they are not typical full
D2 receptor agonists. Neither DHX nor N-propylDHX is able
to inhibit the synthesis and release of dopamine in rat stri-
atum or inhibit the firing of nigral dopaminergic neurons
(Fig. 3) (Kilts et al., 2002; Mottola et al., 2002). Effects in all
of these functional assays would be expected for typical D2
receptor agonists. Thus, although DHX and N-propylDHX
bind to the D2 receptors present in both neural tracks, they
cause differential activation of specific signaling pathways,
an overall concept that led to the coining of the term “func-
tional selectivity” (Lawler et al., 1994, 1999; Mailman et al.,
1997, 1998). Interestingly, the functional selectivity of N-
propylDHX in vitro may explain its unexpected behavioral
effects in vivo (Smith et al., 1997).
Similar trends were observed in vitro (rat lactotrophs as
well as MN9D and Chinese hamster ovary cells stably ex-
pressing the D2 receptor), verifying that the in situ observa-
tions are not artifacts produced by the activation of other
GPCRs and further confirming that functional selectivity as
observed for specific dopaminergic compounds is not an epi-
phenomenon associated with a particular signaling model
(Kilts et al., 2002; Mottola et al., 2002; Gay et al., 2004). This
functionally selective profile is not unique to DHX and N-
propylDHX, as functional selectivity has been shown for
other D2 receptor ligands (e.g., propylnorapomorphine and
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dinapsoline) in vitro (Gay et al., 2004; G. Vargas, S. Chen, A.
Kovoor, B. Feldman, S. Gitelman, S. Rosenthal, and M. von
Zastrow, submitted for publication). Not only have these
latter compounds demonstrated varying intrinsic activities
among the D2 receptor-mediated effectors studied, some of
them also exhibited significant variability in their relative
potencies for the effectors they do activate (Fig. 3).
Ligand-induced differential signaling has been more chal-
lenging to demonstrate in D1 dopamine receptors because
there is a relative paucity of functional effectors known to
couple to this receptor. However, a recent report has shown
that apomorphine seems to regulate D1 signaling differen-
tially, as determined by comparing its ability to fully activate
D1 receptor-mediated cAMP accumulation and its inability to
induce D1 receptor internalization (Ryman-Rasmussen et al.,
2005).
The therapeutic and clinical relevance of functionally se-
lective compounds has been exemplified by the atypical an-
tipsychotic drug aripiprazole (Abilify). By the time it received
approval from the U.S. Food and Drug Administration (Rock-
ville, MD) for the clinical treatment of schizophrenia, aripi-
prazole had been marketed as a partial agonist at both the
5-HT1A and D2 receptors as well as a 5-HT2A antagonist. This
partial D2 agonism (Burris et al., 2002; Cosi et al., 2006) is
postulated to lead to “dopamine system stabilization”, i.e.,
normalization of both dopamine hypoactivity and hyperactiv-
ity in pathologically affected dopaminergic tracts (Stahl,
2001a,b; Tamminga and Carlsson, 2002; Lieberman, 2004).
However, further assessment of the literature reveals that
the intrinsic activity and potency of aripiprazole for the D2-
mediated inhibition of cAMP accumulation is cell line-depen-
dent, as aripiprazole demonstrates weak partial agonist ac-
tivity in the Chinese hamster ovary-D2L cell line but strong
partial agonist activity in human embryonic kidney-D2L cells
(Lawler et al., 1999; Burris et al., 2002; Shapiro et al., 2003).
Moreover, aripiprazole antagonizes both D2 receptor-medi-
ated GTPS binding and GIRK channel activity (Shapiro et
al., 2003) while acting as a full agonist in situ for D2-medi-
ated inhibition of tyrosine hydroxylase (C. Prioleau, C. P.
Lawler, and R. B. Mailman, unpublished observation). Thus
aripiprazole seems to elicit D2-mediated functional effects
that encompass a whole range of classic pharmacological
traits, and its functional properties probably depend on the
signaling machinery associated with the D2 receptor (and
hence, on the type of cell and location in the cell). Indeed, this
conclusion is most consistent with the fact that the drug is
reported to antagonize postsynaptic D2 receptors but par-
tially activate presynaptic D2 autoreceptors (Kikuchi et al.,
1995), Taken together, these data indicate that if “dopamine
stabilization” is a result of aripiprazole treatment, it is pri-
marily via a “correct” mix of direct effects on D2 receptors
rather than “just the right” balance of presynaptic and
postsynaptic actions in competition with dopamine (Urban et
al., 2006).
Mechanisms and Research Directions to
Understand Functional Selectivity
Conformational Changes at the 2AR: Possible
Mechanism of Functional Selectivity
Evidence for multiple receptor states also has been pro-
vided by investigations of agonist-induced conformational
changes in purified 2AR protein. The labeling of specific
sites on the receptor with fluorescent probes (Gether et al.,
1997) allows for the detection of changes in the bound fluoro-
phore, such as fluorescence lifetime, emission maximum,
and/or intensity, and thereby elucidates variations in recep-
tor conformation (Kobilka and Gether, 2002). This approach
has provided evidence that supports the notion that agonists
and partial agonists produce distinct active state conforma-
tions and suggests that agonist binding and activation occur
through a series of discrete conformational intermediates
(Ghanouni et al., 2001; Swaminath et al., 2004).
To understand the multistep process of GPCR activation
better, catecholamine agonist fragments (such as catechol
and dopamine) have been used to study the structural and
functional properties of these conformational intermediate
states (Swaminath et al., 2005). Considering that receptor
activation is thought to result from the ability of an agonist to
disrupt certain intramolecular interactions responsible for
maintaining the basal state of the receptor, it was hypothe-
sized that specific ligand moieties could be employed to real-
ize these interactions.
Swaminath et al. (2005) have reported that catechol, a
weak partial agonist for GTPS binding, was able to activate
the rotamer toggle switch of transmembrane helix 6 (TM6)
but unable to produce a break in the ionic lock between
helices TM3 and TM6. Dopamine, which is able to both acti-
vate the TM6 rotamer toggle switch and break the TM3-TM6
ionic lock, demonstrated strong partial activation of GTPS
binding but failed to induce 2-adrenergic receptor internal-
ization. The extended dopamine congeners norepinephrine
and epinephrine produced additional conformational changes
that promoted receptor internalization, suggesting that a
ligand must induce a number of conformational changes for
typical agonist activity to be satisfied. The noncatechol par-
tial agonist salbutamol, however, is able to break the ionic
lock but fails to activate the rotamer toggle switch. Molecular
Fig. 3. Functional selectivity can be expressed as differences in intrinsic
activity or potency, although the two are interrelated. A, quinpirole and
propyldihydrexidine are full agonists at the D2L receptor in MN9D cells,
whose effects are completely blocked by the D2 antagonist (butaclamol).
B, conversely, only quinpirole inhibits receptor-mediated DA release, and
both propyldihydrexidine and butaclamol block quinpirole effects. C, as
shown in Fig. 2, the relative potency of ligands can be markedly different,
even when the intrinsic activity is the same. Data were from Kilts et al.
(2002) and Gay et al. (2004).
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modeling indicates that the salbutamol aromatic ring does
not interact with the same receptor residues as the catechol
moiety of catecholamines, suggesting that salbutamol in-
duces an active conformation distinct from those induced by
catecholamines (Swaminath et al., 2005).
These results suggest that the disruption of all of the
interactions that maintain the basal conformational state is
not required for a ligand to produce some level of receptor
activation. It is likely that structurally distinct ligands are
able to break different combinations of the basal state-stabi-
lizing interactions either directly by binding to amino acids
that are involved in these intramolecular interactions or
indirectly by stabilizing new intramolecular interactions.
These ligand-specific conformational changes may be respon-
sible for differential activation of the signaling cascades of a
receptor (Swaminath et al., 2005). Furthermore, structurally
distinct ligands are able to break different combinations of
the basal state-stabilizing interactions to produce unique
conformational states, which ultimately may be responsible
for differential activation of the signaling cascades of a re-
ceptor (Swaminath et al., 2005).
Computational and Theoretical Approaches to
Understanding Functional Selectivity
In addressing the apparent disruption of the traditional
thought in pharmacology generated by the functional selec-
tivity phenomenon, there has been a focus on the reasons
that make the observations leading to the definition of “func-
tional selectivity” appear uncommon to classical pharmacol-
ogy. It has been suggested that, to incorporate such appar-
ently discordant observations into the pharmacological
characterization of drug action, it may be necessary to re-
evaluate the current axioms underlying the pharmacological
definitions. This re-evaluation is provoked by experimental
results from newly acquired abilities to 1) identify and test
naturally occurring molecular variations of both receptors
and ligands (e.g., peptide hormones), 2) engineer novel mo-
lecular structures (e.g., constitutively active constructs) that
exhibit new types of pharmacological properties, 3) create
uncommon adjacencies of receptors on the cell surface, allow-
ing for new types of heterodimerizations, and 4) test a much
larger variety (structurally and chemically) of artificially cre-
ated ligands for the receptors. As a result of these develop-
ments, the phenomena that lead to the definition of “func-
tional selectivity” must be examined to establish 1) whether
the novel (or puzzling) phenotypes simply reveal underlying
mechanisms that had not been challenged in classical phar-
macology and 2) whether these mechanisms depend on the
same underlying structure-function rules that explain clas-
sical pharmacology but are richer in phenotypes.
In the context of the latter point, it has been suggested
that the approaches must address structure-based mecha-
nisms for modes of receptor activation, including a mech-
anistic understanding of the molecular processes involved
in the discrimination between agonists and antagonists,
full versus partial agonists, neutral antagonists versus
inverse agonists, and the molecular details of constitutive
activity to various degrees (Ebersole et al., 2003). More-
over, the protein-protein interactions responsible for
homo- and hetero-oligomerization (Filizola and Weinstein,
2005), as well as for the integration of the receptors in the
signaling pathways in the cell (Weinstein, 2006), are likely
to play an important role in determining the properties
underlying the observed departures from what is consid-
ered to be “classical pharmacological activity”.
Point B can be illustrated by examining results from com-
bined experimental and computational approaches applied to
investigating mechanisms essential to the hallucinogenic
drug action of several classes of 5-HT2 receptor compounds.
The goal of this endeavor is to uncover the subtle conse-
quences of ligand-receptor interactions as they are mecha-
nistically related to the subcellular elements ultimately re-
sponsible for hallucinogenic action (reviewed in Weinstein,
2006). It provides an excellent example of apparent pharma-
cological conundrums related to functional selectivity of the
5-HT2A receptor demonstrated by the elegant definition of
the “transcriptome fingerprint” (Gonzalez-Maeso et al.,
2003).
In seeking the structural context of the ligand-determined
receptor mechanisms, this interdisciplinary research has il-
luminated a number of conserved structural motifs in the
configurations of rhodopsin-like GPCRs that are implicated
in receptor signaling by acting as functional microdomains
(Weinstein, 2006). Examples include 1) the NPxxY motif of
TM7 (Prioleau et al., 2002) and 2) the cluster of aromatic
residues in TM6 that straddles a universally conserved pro-
line and is thought to act as a “toggle switch”, thereby con-
veying the consequences of the ligand-binding event to the
rearrangements associated with receptor activation (as re-
viewed in Visiers et al., 2002).
Given this defined set of sites involved in ligand-depen-
dent transitions in the conformation of the GPCRs, these
studies have shown that structurally similar ligands can
produce different ligand-dependent modes of receptor ac-
tivation by aligning themselves in different positions
within the receptor-binding pocket. For example, it seems
that bulky substitutions of the cationic moiety in the hal-
lucinogenic compounds allow these ligands to adopt unique
positions within the 5-HT2A receptor-binding pocket rela-
tive to their nonhallucinogenic congeners (Ebersole et al.,
2003). These observations highlight the idea that ligand-
dependent conformations are able to produce functionally
selective responses at the cellular level that ultimately can
be translated to a unique physiological effect. This mech-
anistic translation depends on the interactions of the re-
ceptor molecule with its environment, such as those in
oligomer formation (see below).
The oligomerization mechanism is only one form of inte-
gration of the GPCR into the signaling networks of the cell,
as different receptor conformations produced by ligand bind-
ing could select for interaction different proteins (e.g., PDZ
domains, kinases) from the downstream signaling pathway
(Fig. 4). Consequently, it is important to integrate the exam-
ination of the putative mechanisms leading to the functional
selectivity paradigm with the subcellular, cellular, and phys-
iological levels of GPCR signaling. A powerful tool for this
integrative approach is quantitative modeling of signaling
pathways as mathematical representations that are amena-
ble to computational simulations (Campagne et al., 2004). To
produce useful models of these signaling systems, the com-
ponents must be represented with the highest level of phys-
ical realism possible at our current understanding of cell
physiology.
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The Potential Role of GPCR Oligomers in Functional
Selectivity
The specific mechanisms of ligand-specific GPCR pathway
activation may also be revealed as more is understood con-
cerning the functional consequences of receptor dimerization/
oligomerization. Many GPCRs have been observed to exist as
homodimers and heterodimers or oligomers, and in some
cases, this heterodimerization has been reported to lead to
novel functional consequences. However, the potential struc-
tural interactions responsible for receptor oligomerization
and cross-talk are largely unknown.
To understand better the functional interactions between
GPCRs, it is necessary to recognize where potential receptor-
receptor interfaces are located. It has been proposed that
functional cross-talk between GPCRs is probably the result of
conformational changes at these dimer interfaces. To inves-
tigate this hypothesis, Guo et al. (2005) have used two rho-
dopsin-based structural models to study the potential dimer
interface of the dopamine D2 receptor. A critical aspect of this
investigation involved mapping the homodimer interface in
the D2 receptor over the entire length of the fourth trans-
membrane segment (TM4) by the cross-linking of substituted
cysteines. The susceptibility of the cysteine mutants to cross-
linking is altered differentially by the presence of agonists
and inverse agonists. The TM4 dimer interface in the inverse
agonist-bound conformation is consistent with the dimer of
the inactive form of rhodopsin modeled with constraints from
atomic force microscopy (Liang et al., 2003). Cross-linking of
a different set of cysteines in TM4 was slowed by inverse
agonists and accelerated in the presence of agonists. Cross-
linking of the latter set locks the receptor in an active state,
as shown in both GTPS binding and cAMP accumulation
assays. Thus, a conformational change at the TM4 dimer
interface is part of the receptor activation mechanism (Guo et
al., 2005). This is shown schematically in Fig. 5.
These results demonstrate that conformational changes in,
and ultimately the rearrangement of, TM4 is critical to the
activation of the D2 receptor dimer and that this aspect of the
dimer interface is coupled to the structure of the binding site
(Guo et al., 2005). It has been proposed that a single hetero-
trimeric G protein may interact with two GPCR protomers
(Baneres and Parello, 2003; Filipek et al., 2004), and confor-
mational changes at the interface may thereby mediate G
protein coupling and activation. Based on X-ray crystallog-
raphy studies of the soluble N-terminal binding sites of
metabotropic glutamate receptors, agonist binding is thought
to alter the relative orientation of the dimer formed by the
two extracellular binding domains (Kunishima et al., 2000;
Tsuchiya et al., 2002; Kniazeff et al., 2004). Moreover, in
metabotropic glutamate receptors, agonist binding has been
shown to lead to a change in the distance between the cyto-
plasmic loops of the protomers (Tateyama et al., 2004). Such
a movement must be associated with an altered relationship
between the transmembrane domains of the two protomers.
Although it has yet to be examined, it is proposed that known
dopamine D2 functionally selective compounds (e.g., dihy-
drexidine, dinapsoline, and aripiprazole) might produce con-
formational changes that generate unique dimer interfaces
that ultimately result in selective dimer-effector coupling.
Impact on Research and Training
The Impact of Functional Selectivity on Quantitative
Pharmacology
The initiation of the era of “analytical pharmacology”, i.e.,
the development and application of quantitative modeling to
describe drug-receptor interactions and their consequences,
can largely be attributed to the work of A. J. Clark. Along
with Clark, the field has continued to develop and progress
thanks in large part to the achievements of E. J. Ariens, J. H.
Fig. 4. The protein-protein interac-
tion interface between a GPCR and its
signaling environment is regulated by
intramolecular interactions involving
the NPxxY motif: The interaction be-
tween Y7.53 and the F7.60, which is
in Hx8, controls the position of the
helix and the C-terminal. This can
regulate the interaction interface be-
tween the GPCRs and other proteins
in the signaling cascade (e.g., PDZ do-
mains) and may be affected differen-
tially by the ligands, providing one
mechanism for functional selectivity.
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Gaddum, H. O. Schild, R. P. Stephenson, R. F. Furchgott, J.
Black, T. P. Kenakin, and others. Indeed, pharmacology, by
its very nature, is a quantitative discipline, and as such
biological and mathematical models are indispensable as
tools for designing and interpreting experiments and provid-
ing objective insights into potential mechanisms of action.
An understanding of the simple model-building process
provides a foundation for subjecting experimental data to
mechanistic scrutiny. There are three possibilities that must
be considered if the data are not in accord with the predic-
tions of the model. 1) The incorporation of more complex
mechanisms into the model is necessary, 2) the assumptions
underlying the model fail to describe accurately the process
used to generate the data, or 3) the process/quality of data
generation needs to be scrutinized.
According to this process, functional selectivity initially
might be described by the simplest mechanism (i.e., a single
state receptor model), as variations in stimulus-response cou-
pling efficiency are sufficient to model many experimentally
observed examples of tissue/cell-dependent differences in the
expression of agonism for a given ligand. If one assumes for
the sake of argument that 2nd and 3rd possibilities described
above do not apply to the experimental approach and result-
ing data, the simplistic premise of a single-state receptor
model becomes clearly inadequate as a mechanism that can
explain phenomena such as reversals in agonist rank poten-
cies, reversals in rank efficacies, and reversals of agonism to
inverse agonism.
One direction for reconciling these experimental observa-
tions is to build more complex drug-receptor models that not
only accommodate our current understanding of protein bio-
physics but also incorporate multiple receptor states (Chris-
topoulos and Kenakin, 2002). The heuristic nature of these
models may yield further insight into biological behavior,
although the very nature of their complexity may sometimes
make it difficult to test the model adequately. A potential
pitfall of multi-state models is the temptation to avoid critical
scrutiny of the underlying assumptions. Thus, the very model
that was built to accommodate novel data might fail to de-
scribe accurately the conditions under which the data were
generated. As an example, the most commonly used multi-
state models assume equilibrium among all reactants, an
assumption that often may not be met. As shown in the
cartoon in Fig. 6, steady-state or kinetic models may provide
Fig. 5. Illustration of potential dimer arrangements and molecular model representations of the proposed dimer interfaces and effects of disulfide
trapping of the respective interfaces on receptor activation (see Guo et al., 2005 for additional detail). Left, extracellular and side views of a symmetric
TM4-TM5 interface (yellow) as proposed by Liang et al. (2003). Right, extracellular and side views of a symmetric TM4 interface (red) deduced from
the squid rhodopsin two-dimensional electron density map (Davies et al., 2001). These two models are proposed to correspond to the inactive and active
states, respectively. The backbone of the transmembrane segments is rendered as cylinders. Middle, the change in [cAMP] in the presence of forskolin
(100 M) after treatment with copper (phenanthroline)2 (100 M) in cells stably expressing the appropriate cysteine mutants is shown as the mean 
S.E.M. (n  3–6). The x-axis is plotted so that activation of the receptor, which causes inhibition of adenylate cyclase through Gi, is shown to the right
of the y-intercept. In C1684.58S, the maximal change of cAMP induced by dopamine was74%. Thus, disulfide trapping of residues at the red interface
activates the receptor, whereas cross-linking of residues at the yellow interface decreases spontaneous activation.
Fig. 6. The three different types of models applied to biological systems
are amenable to a pendulum analogy. Equilibrium models, which encom-
pass the ternary complex model (TCM), extended TCM (ETCM), and
cubic TCM (CTCM) are akin to a pendulum that is static in nature.
Steady-state models, such as the ternary complex activation model
(TCAM), are more realistic in that they encompass the contribution of
energy (e.g., wind for the pendulum) to maintain a behavior that appears
static. The most biologically relevant models, however, are dynamic mod-
els, because they reflect the fact that the system is constantly changing in
time. However, the more biologically relevant, the more complex the
model becomes. Adapted from Woolf and Linderman (2000).
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more realistic mechanisms for understanding biological be-
havior under such circumstances (Christopoulos et al., 1999;
Lew et al., 2000; Woolf and Linderman, 2000). Indeed, it may
be that it is timely to bring nonlinear dynamic approaches
into the receptor pharmacology arena.
Functional Selectivity: Do We Need to Update
Pharmacological Terminology?
In light of the pharmacological questions raised by the
concept of functional selectivity, there is a need to appropri-
ately classify GPCRs and the novel mechanisms that have
been put forth to describe adequately the anomalies observed
in functional pharmacology. In fact, the Nomenclature Com-
mittee of the International Union of Basic and Clinical Phar-
macology (NC-IUPHAR) is developing a plan to initiate such
a project. The mission of NC-IUPHAR is to 1) issue guide-
lines for receptor and ion channel classification, 2) classify
the major receptor and ion channel systems, and 3) facilitate
the interface between discovery of new sequences from the
human genome project and designation of the derived pro-
teins as functional receptors and ion channels.
Indeed, the publication of the human genome project
marks a unique moment in scientific history in that all of the
potential sequences for receptors and ion channels that have
any analogy to previously known classes are now available. It
is unlikely that many new ion channels or receptors have yet
to be discovered, so it is the mechanistic understanding of
these hypothesized ion channel and receptor sequences (as
well as their biologically important polymorphisms) that is
presently an important pursuit of the medical and pharma-
cological community. The initial difficulties lie in the fact
that the primary receptor sequences must be linked to gen-
eral pharmacology, as well as to the affinity and potency
values of classic agonists and antagonists. However, it is
clear that, for standard receptor sequences, there can be
extremely diverse affinities and potencies reported in the
literature (for a hands-on example of this the reader is re-
ferred to http://pdsp.cwru.edu/pdsp.asp, an interactive data-
base of ligand-receptor affinities resulting from the National
Institute of Mental Health-sponsored Psychoactive Drug
Screening Program in Bryan Roth’s laboratory, and to the
IUPHAR website, www.iuphar-db.org).
If functional selectivity is indeed a crucial mechanism that
must be considered in the drug development process, initial
screens using reconstituted systems may not show the ap-
propriate pharmacology. To select the best compounds (or
indeed to understand selected lead compounds), assays de-
pendent on several effector systems are necessary to screen
for differential activation. This will provide a more accurate
reflection of the characteristics of given compound, but even
then, appropriate in vivo physiological models will still be
required. This clearly creates a massive but necessary task
for pharmacologists as was recently proposed in detail (Sped-
ding et al., 2005). If this is the case, drug discovery may be
back to drug-specific pharmacology (where each drug may
have a distinct profile), rather than specific-drug pharmacol-
ogy (where agents specific for a receptor have a predicted
action). This is particularly the case for nuclear receptors
where the local availability of coactivators and corepressors
markedly modifies drug responses (NC-IUPHAR reports in
preparation).
Functional Selectivity and Its Impact on Drug Discovery
There are two general questions concerning functional se-
lectivity as it relates to industry. 1) Can functional selectivity
be observed during the GPCR drug discovery process, espe-
cially within in vitro systems? 2) If observed, can functional
selectivity in vitro be applied toward measures of in vivo
efficacy and/or safety liabilities?
Of course, the answer to the first question is “yes”. Func-
tional selectivity is often observed with GPCRs expressed in
recombinant systems, which can have an immediate impact
on lead identification. However, high-throughput screening
(HTS) campaigns often employ a single functional endpoint
with which to characterize the activities of test compounds,
an approach that can potentially lead to overlooking or tri-
aging important compounds that signal through alternative
pathways via the same receptor. For example, it has been
demonstrated with both 5-HT2C and D2 ligands that rela-
tively small structural modifications can elicit functional se-
lectivity (more than 100-fold) without affecting receptor af-
finity (Miller et al., 2000; Gay et al., 2004). Therefore, it is
important to collect data on ligand affinity and activity
through multiple functional endpoints. However, within the
realm of industry, the addition of multiple functional effec-
tors to a HTS operation is a substantial additional cost, and
it is partially for this reason that industry has been slow to
move in this direction.
Even when functional selectivity can be demonstrated in
vitro, it is not completely clear how it may affect in vivo
efficacy and/or improved safety profiles. The 5-HT2C com-
pounds that illustrated functionally selective profiles in vitro
(i.e., high 5-HT2C receptor affinity, high GTPS potency, but
a 100-fold lower potency for the 5-HT2C-mediated production
of IP3) were found to produce a similar level of efficacy in both
acute and chronic feeding models as those compounds con-
sidered typical potent 5-HT2C receptor agonists (Largent et
al., 2002). Further in vivo examination of c-Fos activation in
regions of the brain known to be involved in appetite regu-
lation showed no difference among the compounds in the
number or localization of activated neurons. Conversely, pro-
pyldihydrexidine (Fig. 3), a compound with functionally se-
lective in vitro properties (Kilts et al., 2002), causes quite
unexpected behavioral effects (Smith et al., 1997). These
examples highlight the immaturity of this field and the need
for additional research.
Ultimately, functional selectivity is a concept that must be
considered when dealing with drug discovery. Both further
discovery and a better understanding of the multiple signal-
ing pathways coupled to various GPCRs will allow for the
design of more integrated HTS assays and thus lead to more
informed interpretations of ligand-receptor structure-activ-
ity relationships. Appreciating this concept also may help to
explain unexpected in vivo findings of functionally weak com-
pounds that illustrate in vivo efficacies equivalent to typical
agonists.
Future Directions
A major point of discussion is how these observations of
functionally selective ligands might affect traditional phar-
macological principles from the bench and clinic to the class-
room. For example, there is the line of thinking that the
underlying mechanisms for this phenomenon should be more
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carefully illuminated before a significant push is made to
establish functional selectivity as an accepted pharmacolog-
ical mechanism. Proponents for this more conservative ap-
proach feel that current knowledge of local receptor milieus,
the involvement of accessory and structural proteins in sig-
naling, receptor dimerization, kinetics, and so forth is rather
limited and that this uncertainty opens the door for a variety
of mechanisms that might provide alternate explanation(s)
without requiring major revisions in current pharmacological
theory.
Although it is clear that there are many gaps in our knowl-
edge of receptor signaling, it seems to us that functional
selectivity is a real phenomenon with a plethora of support-
ing examples. Indeed, we are not aware of any data from
appropriately controlled studies that invalidate the func-
tional selectivity hypothesis. Furthermore, some receptor
mutations have been shown to cause standard ligands to
become functionally selective or to alter the signaling pattern
of existing functionally selective ligands. As such, the concept
must be given wider consideration by pharmacologists be-
cause of its potential relevance to both mechanistic interpre-
tation of data, as well as its impact on ligand characterization
and even drug discovery. We might consider, as an example,
the dynamic nature of ligand-receptor modeling that has
been continually updated as new data and new methodolo-
gies have been incorporated. Of course, the basic pharmaco-
logical tenet of “intrinsic efficacy” is particularly difficult
because of the inability to reconcile it with so many examples
of functional selectivity.
If one accepts that functional selectivity is a widely appli-
cable phenomenon (regardless of whether or not it requires
scrapping of traditional quantitative pharmacology), it seems
clear that it will affect the way that pharmacology is taught.
If the concept proves to be universal, it will have an impact
directly on the training of future scientists who will affect
future research and drug discovery. How this more compli-
cated mechanism will be taught to others (e.g., medical or
pharmacy students) is a challenge that will certainly need to
be sorted out.
Another major point of discussion relates to the agreement
on a common name for functional selectivity to avoid a phar-
macological Tower of Babel. As noted in the Introduction,
this phenomenon carries many monikers, some of which have
different connotations to what is being described. What is
evident from the data is that the examples of GPCR ligands
considered to be “functionally selective” run the gamut in
terms of their functional profiles. Thus, there are examples of
ligands that have a broad functional profile for a specific
receptor (antagonist or inverse agonist through full-agonist
behaviors), whereas others demonstrate less drastic differ-
ences in their receptor-specific functional activity (e.g., full-
and partial-agonist activity). Some current terms imply ei-
ther specific mechanisms or a narrow range of functional
possibilities (e.g., “protean agonism”, “agonist-directed traf-
ficking of stimulus”, and “biased agonism”). These terms fail
to accommodate situations in which there is functional “in-
activity” (i.e., antagonism), and the use of the term “traffick-
ing” is often confused with established terminology that de-
scribe receptor relocalization. Another phrase, “relative
activity versus endocytosis (RAVE)”, although a catchy acro-
nym, is mechanistically restrictive.
Although the term “functional selectivity” is descriptive
and mechanistically neutral (both desirable characteristics),
its use to describe the concept of ligand-dependent differen-
tial regulation of receptor-coupled effector pathways is weak-
ened by the fact that a PubMed search for “functional selec-
tivity” results in 133 hits. Of these, only a few actually refer
to the concept of ligand-dependent differential regulation of
signaling via a single receptor (the concept inherent to this
Perspective), whereas the majority uses the phrase in a man-
ner that describes ligand activity as a function of receptor
subtype. Thus, although “functional selectivity” may convey
an appropriately neutral functional tone, its “misuse” in the
literature may potentially create confusion for future publi-
cation on the issue. A term that has been suggested as a
viable alternative is “ligand-induced differential signaling”.
It also is mechanism-neutral, would not be confused with
other aspects of cellular signaling and regulation, and evokes
a catchy acronym. The importance of an appropriate mecha-
nistic classification of functional selectivity has been echoed
by members of the Nomenclature Committee of IUPHAR. In
fact, the NC-IUPHAR urges those who are interested to
actively participate in the ongoing dialog on the issue of
terminology by submitting their opinions directly (http://
www.iuphar.org/nciuphar.html). It is important to note that,
although this Perspective has taken a GPCR-centric view of
the receptor world, we are keenly aware that similar phe-
nomena (e.g., selective estrogen receptor modulation) have
been recognized with other receptor superfamilies (e.g., see
Gronemeyer et al., 2004 for recent review). Thus, the impact
of this issue spans the breadth of pharmacology
In closing, there is a need for even greater understanding
of local receptor environments and the factors that might
play a role in the types of anomalous observations reviewed
here. These range from accessory proteins (both catalytic and
organizational), receptor dimerization (both homodimers and
heterodimers), alternative receptor splicing, mRNA editing,
receptor polymorphisms (single nucleotide polymorphisms),
trafficking of receptors, and so on. There is also a need to
understand how subtle changes in ligand structure can some-
times have profound effects on functional properties. Not
only will such data provide a firm mechanistic base for func-
tional selectivity (by whatever name it is called), this knowl-
edge also will help us to understand many apparent pharma-
cological anomalies and potentially lead to novel drug
discovery. Some years ago, it was written that functional
selectivity “. . . could yield important therapeutic advances,
although it introduces a new level of complexity that will
require significantly greater understanding of receptor dy-
namics and the interaction with transduction mechanisms”
(Mailman et al., 1997, 1998). The discussions resulting from
the paradoxical data found in the literature suggest that the
time is ripe to explore these issues further.
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